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Abstract
Background: Increased serum level of parathyroid hormone (PTH) was found in metastatic
prostate cancers. Calcimimetic R-568 was reported to reduce PTH expression, to suppress cell
proliferation and to induce apoptosis in parathyroid cells. In this study, we investigated the effect
of R-568 on cellular survival of prostate cancer cells.
Methods: Prostate cancer cell lines LNCaP and PC-3 were used in this study. Cellular survival was
determined with MTT, trypan blue exclusion and fluorescent Live/Death assays. Western blot assay
was utilized to assess apoptotic events induced by R-568 treatment. JC-1 staining was used to
evaluate mitochondrial membrane potential.
Results: In cultured prostate cancer LNCaP and PC-3 cells, R-568 treatment significantly reduced
cellular survival in a dose- and time-dependent manner. R-568-induced cell death was an apoptotic
event, as evidenced by caspase-3 processing and PARP cleavage, as well as JC-1 color change in
mitochondria. Knocking down calcium sensing receptor (CaSR) significantly reduced R-568-
induced cytotoxicity. Enforced expression of Bcl-xL gene abolished R-568-induced cell death, while
loss of Bcl-xL expression led to increased cell death in R-568-treated LNCaP cells,.
Conclusion: Taken together, our data demonstrated that calcimimetic R-568 triggers an intrinsic
mitochondria-related apoptotic pathway, which is dependent on the CaSR and is modulated by Bcl-
xL anti-apoptotic pathway.
Introduction
Calcimimetic agents, like NPS R-568 (Cinacalcet HCl), is
an allosteric agonist for parathyroid calcium-sensing
receptor (CaSR) and was shown to lower circulating levels
of parathyroid hormone (PTH) in patients with secondary
hyperparathyroidism due to late-stage renal diseases
[reviewed in [1,2]]. In addition, studies have shown that
CaSR is involved in cell differentiation and apoptosis in
osteoblast cells [3] and NPS R-568 treatment induced
apoptotic cell death in hyperplastic parathyroid cells [4].
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In the literature, clinical reports have shown that
increased levels of serum PTH was frequently found in
advanced prostate cancers [reviewed in ref. [5]], since the
first description of possible secondary hyperparathy-
roidism (SHPT) as an accompanied syndrome with late-
stage prostate cancer patients more than 46 years ago [6].
In theory, osteoblastic lesion in skeletal sites of metastatic
prostate cancer causes hypocalcemia that in turn leads to
calcium-sensing receptor (CaSR) activation, resulting in
increased PTH production and secretion [5,6]. Mean-
while, PTH has been shown to increase cell proliferation
of human prostate cancer in vitro [7] and to promote bone
metastasis in mouse xenograft model of prostate cancer
[8]. Therefore, reducing PTH secretion could potentially
interrupt SHPT and be of substantial clinical benefit in
prostate cancer patients.
In fact, a functional CaSR was detected in human prostate
cancer cells [9,10]. However, the biological effect of cal-
cimimetic agents on prostate cancer cells has not been
evaluated. Therefore, in this study, we tested the biologi-
cal effect of calcimimetic agent NPS R-568 on multiple
prostate cancer cells. We surprisingly found for the first
time that NPS R-568 induced apoptotic cell death, which
is dependent on the CaSR and is modulated by anti-apop-
totic Bcl-xL pathway.
Materials and methods
Cell Culture, Reagents and Antibodies
Human prostate cancer PC-3 and LNCaP, as well as
LNCaP sublines (LNCaP/Bclxl and LNCaP/LN11) were
described in our previous publication [11]. Briefly,
LNCaP/Bclxl cells were established by stable transfection
of LNCaP cells with a vector bearing HA-tagged human
bcl-xl cDNA sequence (pcDNA3.1-Bclxl.HA). LN11 is a
LNCaP cell subline that lost Bcl-xL expression, as
described [11]. Cells were maintained in a humidified
atmosphere of 5% CO2, RPMI 1640 supplemented with
10% fetal bovine serum (FBS) with antibiotics (Invitro-
gen, Carlsbad, CA). Antibodies for PARP, caspase-3, CaSR
and Actin were purchased from Santa Cruz Biotech (Santa
Cruz, CA). CaSR small interference RNA (siRNA) mixture
and the negative control siRNA were obtained from Santa
Cruz Biotech. The calcimimetic R isomer of N-[3-[2-chlo-
rophenyl]propyl]-[R]-α-methyl-3-methoxybenzylamine
(NPS R-568) and its inactive isomer NPS S-568 were
kindly provided by Amgen, Inc. (Thousand Oaks, CA).
Cell Viability Analyses
For MTT [3-[4,5-dimethylthazol-2-yl]-2,5-diphenyl tetra-
zolium-Bromide] assay, which is based on the conversion
of MTT to MTT-formazan by mitochondrial enzyme, a cell
growth determination kit (Sigma Co., St Louse, MO) was
utilized according to the instruction from the manufac-
turer. Briefly, cells were seeded at a density of 2 × 103 cells/
well in 96-well plates in triplicates and allowed to attach-
ment overnight. Cells were then maintained in various
conditions as indicated in the figures. The MTT solution
was added in an amount equal to 10% of the culture vol-
ume. After 3 h incubation, the culture media was removed
and the MTT solvent was added. The plates were read at a
wavelength of 570 nM.
For trypan blue assay, cells were seeded in 12-well plates,
and then treated with various reagents as indicated in the
figures. At the end of experiments, viable cells was
counted using a hemocytometer after staining with trypan
blue as described in our recent publication [11].
For siRNA transfection, cells were plated in 6-well plates
and transfected with the siRNA mixture as indicated in the
figure using OligoTransfectamine™ (Invitrogen, Carlsbad,
CA), as described in our previous publication [11]. Three
days after transfection, cells were treated with the R568 at
the concentrations indicated in the figure. Cellular sur-
vival was assessed with trypan blue exclusion assay.
To assess the cell death objectively, a LIVE/DEAD® Viabil-
ity/Cytotoxicity kit (Invitrogen, Carlsbad, CA) was uti-
lized. This kit provides two molecular probes, of which
one probe labels the living cells as green based on an
intracellular esterase activity and the other probe simulta-
neously labels the dead cells as red due to the disruption
of plasma membrane integrity. The assay was conducted
by following the protocol provided by the manufacturer.
Briefly, cells were placed in 24-well plates overnight, and
treated with R-568 for different time periods as indicated
in the figures. At each time points, cells were incubated
with the fluorescent dyes (2.0 μM) for 15 min before
micro-images were taken under a fluorescent microscope.
Mitochondrial Membrane Potential (JC-1) assay
To examine the change of mitochondria membrane
potential, JC-1 staining assay was used, as described in our
previous publication [11]. Briefly, after treatment with R-
568 or S-568 for 24 h, cells were incubated in the presence
of JC-1 (Cell Technology Inc., Mountain View, CA) at a
final concentration of 0.3 μg/ml for 15 minutes at 37C.
Thereafter, the cells were analyzed under a fluorescent
microscope.
Western Blot Analysis
Western blot was carried out as described previously [11].
Briefly, cells were pelletted and lysed in a buffer contain-
ing protease inhibitors (Half™ Protease Inhibitor Cocktail
Kit, PIERCE, Rockford, IL). Equal amounts of proteins
were separated on SDS-PAGE gels and transferred to PVDF
membrane (BIO-RAD, Hercules, CA). Membranes were
blocked in a Tris-buffered solution plus 0.1% Tween 20
(TBS-T) solution with 5% nonfat dry milk and incubatedJournal of Experimental & Clinical Cancer Research 2009, 28:100 http://www.jeccr.com/content/28/1/100
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with primary antibodies overnight at 4C. Immunoreactive
signals were detected by horseradish peroxidase-conju-
gated secondary antibodies and chemiluminescence sub-
strate purchased from (Santa Cruz Biotech., Santa Cruz,
CA).
Statistical Analysis
All cell culture-based experiments were repeated two or
three times. Western blots are presented from representa-
tive experiments. The mean and SEM for cell viability
assay are shown. The significant differences between
groups were analyzed as described in our previous publi-
cation [11], using the SPSS computer software (SPSS Inc.,
Chicago, IL).
Results
The calcimimetic R-568 but not S-568 induces cell death in 
prostate cancer cells
The calcimimetic agent R-568 has been shown to activate
CaSR and to induce apoptotic cell death in parathyroid
cells in addition to reducing PTH secretion [1-3]. In this
study, we evaluated R-568-induced effect on cellular sur-
vival in two prostate cancer cell lines, androgen receptor-
positive LNCaP cells and androgen receptor-negative PC-
3 cells. LNCaP cells were derived from lymph node metas-
tasis of prostate cancer, while PC-3 cell line was estab-
lished from a bone metastasis of human prostate cancer.
In a MTT assay, as shown in Fig 1A &1B, the calcimimetic
R-568 but not its negative isomer S-568, which does not
activate CaSR, significantly reduced cellular viability in
both LNCaP and PC-3 cells, of which PC-3 showed a
higher sensitivity to R-568 treatment compared to LNCaP
cells. In a trypan blue exclusive assay, R-568 treatment
exhibited similar cytotoxicity in both LNCaP and PC-3
cell lines in a dose-dependent manner (Fig 1C). However,
silencing the CaSR significantly attenuated R-568-induced
cell death as compared to the negative siRNA in PC-3 cells
(Fig 1D). These data demonstrated for the first time that
the calcimimetic agent R-568 is capable of inducing cell
death in prostate cancer cells, regardless the status of
androgen receptor gene expression, and CaSR activation
might play an essential role in R-568-induced cell death.
To further illustrate the death inducing effect induced by
R-568 treatment, we utilized a Live/Dead assay to objec-
tively evaluate cell death. As shown in Fig 2, both cell lines
of LNCaP and PC-3 cells showed a time-dependent death
response after treatment with R-568 (100 μM). These data
confirmed R-568-induced cell death in prostate cancer
cells.
The calcimimetic R-568-induced cell death is an apoptotic 
event in prostate cancer cells
It has been shown that CaSR activation is involved in oste-
oblast cell apoptosis [4] and R-568 treatment induces
apoptotic cell death in rat parathyroid cell [3]. Therefore,
we asked if R-568-induced cell death was an apoptotic
response in LNCaP and PC-3 cells. We utilized the most
commonly used apoptotic markers, caspase-3 processing
and PARP cleavage, in our next experiments. As shown in
Fig 3 (panel A and panel B), R-568 treatment resulted in a
remarkable processing of caspase-3 and a clear pattern of
PARP cleavage in both LNCaP and PC-3 cells, indicating
that R-568-induced cell death is an apoptotic response.
To further characterize R-568-induced apoptosis, we
examined the change of mitochondrial membrane poten-
tial using the JC-1 dye, which accumulates in the mito-
chondria of viable cells as aggregates, which are
fluorescent red in color. Conversely, in apoptotic cells, the
mitochondrial potential collapses and the JC-1 dye could
no longer accumulate in the mitochondria and remains in
the cytoplasm in a monomeric form which fluoresces
green. As shown in Fig 3C, treatment with R-568 but not
S-568 induced a dramatic change of JC-1 color/distribu-
tion from red/puncture pattern to green/defused pattern,
suggesting that R-568 treatment induced a severe damage
to mitochondria, which is consistent with the data shown
in Fig 3A and Fig 3B. Taken together, these data strongly
suggest that the calcimimetic agent R-568 induced apop-
totic cell death via a mitochondria-related mechanism.
The calcimimetic R-568-induced apoptosis is modulated 
by anti-apoptotic protein Bcl-xL
Anti-apoptotic protein Bcl-xL is mainly localized on the
mitochondrial membrane and plays an important role in
maintenance of membrane potential [12]. Recent studies
from our group and others showed that Bcl-xL is a major
cellular survival factor in castration-resistant prostate can-
cers [11,13-15]. Therefore, we evaluated if Bcl-xL modu-
lates R-568-induced apoptosis. Two previously confirmed
LNCaP sublines, LNCaP/Bclxl (Bcl-xL overexpression)
and LNCaP/LN11 (Bcl-xL null) described in our recent
publication [11], were used in a trypan blue exclusion
assay. Compared to the parental LNCaP cells, enforced
Bcl-xL expression abolished R-568-induced cell death in
LNCaP/Bclxl cells while loss of Bcl-xL expression signifi-
cantly increased R-568-induced cell death in LNCaP/
LN11 cells [Fig 4A]. Consistently, caspase-3 processing
and PARP cleavage were also dramatically attenuated due
to altered levels of Bcl-xL expression in response to R-568
treatment [Fig 4B]. These data further confirmed that R-
568-induced cytotoxicity is due to mitochondria-related
mechanism in prostate cancer cells.
Discussion
The primary goal of this study was to determine the bio-
logical effect of the calcimimetic NPS R-568 on prostate
cancer cells. Using two commonly used prostate cancer
cell lines, AR-positive LNCaP and AR-negative PC-3, weJournal of Experimental & Clinical Cancer Research 2009, 28:100 http://www.jeccr.com/content/28/1/100
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R-568 reduces cell viability in prostate cancer cells Figure 1
R-568 reduces cell viability in prostate cancer cells. A&B Cells were seeded in 96-well plates overnight and then 
treated with R-568 or S-568 at the indicated doses. Control cells received no treatment. After 48 h, viable cells were deter-
mined using a MTT assay kit (Sigma, St Louise, MO). The average values of optical densities from each group were presented. 
Data represents three separate experiments. The red dotted line indicates the IC50 value. C Cells were plated in 12-well 
plates and treated with R-568 at the indicated doses for 48 h. The control cells received no treatment. Cells were harvested at 
the end of experiment and stained in 0.4% trypan blue solution. The dead (blue) cells were counted and the average of death 
rate in each well was presented. D PC-3 cells were plated in 6-well plates and then transfected with negative control siRNA or 
CaSR siRNA at 100 μM final concentration in the culture media. Two days later, cells were treated with the solvent or R-568 
(50 μM) for 48 hours. Cell death rate was assessed using trypan blue exclusion assay as described earlier. INSERT: Two days 
after the siRNA transfection, PC-3 cells were treated with or without R-568 for 48 h. Cell lysates were subjected to Western 
blot for assessing CaSR protein levels. Actin blot served as protein loading control. Data represents three different experi-
ments. The asterisk indicates a significant difference (P < 0.05, Student t-test) between R-568 treatment and the control.Journal of Experimental & Clinical Cancer Research 2009, 28:100 http://www.jeccr.com/content/28/1/100
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demonstrated that R-568 reduced cell viability of both cell
lines in a dose- and time-dependent manner. R-568-
induced cell death is an apoptotic response through a
mitochondria-related mechanism and CaSR is essential
for R-568-induced cell death. These data provided the pre-
liminary evidence that the calcimimetic R-568 might be
useful as adjunctive therapeutic agent for advanced pros-
tate cancers although further pre-clinical testing is desira-
ble.
Currently, limited information is available for calcimi-
metic NPS R-568-induced apoptosis in mammalian cells.
In this study, we showed that R-568 treatment disrupted
mitochondrial membrane potential and that modulation
of the anti-apoptotic protein Bcl-xL expression attenuated
R-568-induced caspase-3 activation and cell death, sug-
gesting that an intrinsic apoptosis pathway is triggered by
R-568 treatment. In both LNCaP and PC-3 cells, R-568-
induced cell death was found in a range of concentrations
that are similar to the doses used in a recent report to
induce apoptosis in isolated rat parathyroid cells [3]. The
calcimimetic agents have been reported to increase intrac-
ellular calcium concentration in a dose-dependent man-
ner [16], and calcium accumulation in mitochondria has
been considered as a major apoptotic mechanism
[reviewed in ref. [17]]. Thus, it is plausible that R-568
increased cytosolic calcium, leading to calcium accumula-
tion and mitochondrial stress, eventually resulting in
apoptotic cell death. Further investigation in this aspect is
underway by our group.
CaSR signaling has been studied in multiple cancers and
different effects were reported depending on the cell types
and agonists used [reviewed in ref. [18]]. For example, in
R-568 induces cell death in prostate cancer cells Figure 2
R-568 induces cell death in prostate cancer cells. LNCaP and PC-3 cells were plated in 24-well plates overnight, and 
then treated with R-568 (100 μM) for up to 48 h. At each time points as indicated, the fluorescent dyes (2.0 μM) were added 
into the culture media and cells were incubated for 15 min before micro-images were taken under a fluorescent microscope 
(panel A, magnification × 200). Quantitative data for the percentage of dead cells (red-labeled cells) in the total cells (red plus 
green cells) were summarized in panel B as mean ± SEM from 5 microscopic fields). The asterisk indicates a significant differ-
ence (P < 0.01, Student t-test) as compared to the value at the 0 hour time point.Journal of Experimental & Clinical Cancer Research 2009, 28:100 http://www.jeccr.com/content/28/1/100
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R-568-induced cell death is an apoptotic response in prostate cancer cells Figure 3
R-568-induced cell death is an apoptotic response in prostate cancer cells. A&B LNCaP and PC-3 cells were treated 
with R-568 (50 μM) for different time period as indicated. Equal amounts of cellular proteins were subjected to Western blot 
assay to assess caspase-3 processing and PARP cleavage. Primary antibodies used are indicated on the left side. Actin blot 
served as the protein loading control. Data represent two different experiments. C LNCaP and PC-3 cells were seeded in 8-
well chambered glass slides overnight. Following treatment with R-568 or S-568 at a dose of 50 μM for 24 h, cells were incu-
bated with JC-1 (0.3 μg/ml) for 15 min at 37C. Pictures were taken under a fluorescent microscope. Magnification × 200.Journal of Experimental & Clinical Cancer Research 2009, 28:100 http://www.jeccr.com/content/28/1/100
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parathyroid adenoma and colon cancers, loss of CaSR
expression was reported, leading to uncontrolled growth
due to elevated calcium level. In prostate cancers, calcium-
mediated CaSR activation was reported to prevent apop-
tosis [19], and to stimulate cell proliferation [20], and to
increase production of PTH-related protein (PTHrP), a
causal factor in bone metastasis [9,10]. On the other
hand, CaSR-mediated apoptosis was also reported in oste-
oblast and human embryonic kidney cells [4,21], espe-
cially the calcimimetic R-568-induced apoptotic cell
death in hyperplastic parathyroid cells [3]. Consistently,
in this study, we provided the first evidence that R-568 but
not its negative isomer S-568 induces apoptotic cell death
in human prostate cancer cells, and that R-568-induced
cell death is via a CaSR-dependent pathway.
In conclusion, we demonstrated that the calcimimetic R-
568 induces apoptotic cell death in prostate cancer cells.
R-568-induced apoptotic cell death is via a mitochondria-
related pathway. The usefulness of the calcimimetic agent
in managing prostate cancer patients needs further testing
in pre-clinical and clinical study.
Abbreviations
AR: androgen receptor; CaSR: calcium sensing receptor;
FBS: fetal bovine serum; MTT: [3-[4,5-dimethylthiazol-2-
yl]-2,5-diphenyltetrazolium bromide]; PARP: poly [ADP-
ribose] polymerase; PBS: phosphate-buffered saline; PTH:
parathyroid hormone; PTHrP: PTH-related protein; SEM:
standard error of mean; SHPT: secondary hyperparathy-
roidism; TBS-T: Tris-buffered solution plus Tween 20.
Competing interests
The authors declare that they have no competing interests.
Authors' contributions
HL, BL and MZ designed the experiments, HL, GR partici-
pated in most of the experiments, ZL and XZ carried out
the siRNA experiments, HZ and GC conducted the JC-1
experiments, HL and MZ drafted the manuscript. BL was
involved in design of the study and performed the statisti-
cal analysis and helped to finalize the manuscript. All
authors read and approved the final manuscript.
Acknowledgements
We sincerely thank Amgen, Inc. for providing the NPS R-568 and S-568 rea-
gents. This study was supported in part by KUMC William L. Valk Founda-
tion, grants from KU Mason's Foundation and KUMC Lied Foundation to 
Dr Benyi Li.
References
1. Nagano N: Pharmacological and clinical properties of calcimi-
metics: calcium receptor activators that afford an innovative
approach to controlling hyperparathyroidism.  Pharmacol Ther
2006, 109:339-365.
2. Torres PU: Cinacalcet HCl: a novel treatment for secondary
hyperparathyroidism caused by chronic kidney disease.  J Ren
Nutr 2006, 16:253-258.
3. Mizobuchi M, Ogata H, Hatamura I, Saji F, Koiwa F, Kinugasa E,
Koshikawa S, Akizawa T: Activation of calcium-sensing receptor
accelerates apoptosis in hyperplastic parathyroid cells.  Bio-
chem Biophys Res Commun 2007, 362:11-16.
4. Mentaverri R, Yano S, Chattopadhyay N, Petit L, Kifor O, Kamel S,
Terwilliger EF, Brazier M, Brown EM: The calcium sensing recep-
tor is directly involved in both osteoclast differentiation and
apoptosis.  FASEB J 2006, 20:2562-2564.
5. Schwartz GG: Prostate cancer, serum parathyroid hormone,
and the progression of skeletal metastases.  Cancer Epidemiol
Biomarkers Prev 2008, 17:478-483.
6. Ludwig GD: Hypocalcemia and hypophosphatemia accompa-
nying osteoblastic osseous metastases: studies of calcium
and phosphate metabolism and parathyroid function.  Ann
Intern Med 1962, 56:676-677.
7. Ritchie CK, Thomas KG, Andrews LR, Tindall DJ, Fitzpatrick LA:
Effects of the calciotrophic peptides calcitonin and parathy-
R-568-induced apoptosis is attenuated by altered Bcl-xL  expression in prostate cancer cells Figure 4
R-568-induced apoptosis is attenuated by altered Bcl-
xL expression in prostate cancer cells. A LNCaP cells 
and its two sublines, LNCaP/Bclxl and LNCaP/LN11, were 
seeded in 12-well plates and treated with R-568 at the indi-
cated doses for 48 h. The control cells received no treat-
ment. Cells were harvested at the end of experiment and 
stained in 0.4% trypan blue solution. The dead (blue) cells 
were counted and the average of death rate in each well was 
presented. Data represent three different experiments. The 
asterisk indicates a significant difference (P < 0.05) between 
R-568 treatment and the control. B LNCaP/Bclxl and 
LNCaP/LN11 cells were treated with R-568 at indicated 
doses for 24 h and then harvested for protein extraction. 
Equal amounts of cellular proteins were subjected to West-
ern blot assay to assess caspase-3 processing and PARP 
cleavage. Primary antibodies used are indicated on the left 
side. Actin blot served as the protein loading control. Data 
represent two different experiments.Publish with BioMed Central    and   every 
scientist can read your work free of charge
"BioMed Central will be the most significant development for 
disseminating the results of biomedical research in our lifetime."
Sir Paul Nurse, Cancer Research UK
Your research papers will be:
available free of charge to the entire biomedical community
peer reviewed and published  immediately upon acceptance
cited in PubMed and archived on PubMed Central 
yours — you keep the copyright
Submit your manuscript here:
http://www.biomedcentral.com/info/publishing_adv.asp
BioMedcentral
Journal of Experimental & Clinical Cancer Research 2009, 28:100 http://www.jeccr.com/content/28/1/100
Page 8 of 8
(page number not for citation purposes)
roid hormone on prostate cancer growth and chemotaxis.
Prostate 1997, 30:183-187.
8. Schneider A, Kalikin LM, Mattos AC, Keller ET, Allen MJ, Pienta KJ,
McCauley LK: Bone turnover mediates preferential localiza-
tion of prostate cancer in the skeleton.  Endocrinology 2005,
146:1727-1736.
9. Sanders JL, Chattopadhyay N, Kifor O, Yamaguchi T, Brown EM:
Ca(2+)-sensing receptor expression and PTHrP secretion in
PC-3 human prostate cancer cells.  Am J Physiol Endocrinol Metab
2001, 281:E1267-E1274.
10. Yano S, Macleod RJ, Chattopadhyay N, Tfelt-Hansen J, Kifor O, But-
ters RR, Brown EM: Calcium-sensing receptor activation stim-
ulates parathyroid hormone-related protein secretion in
prostate cancer cells: role of epidermal growth factor recep-
tor transactivation.  Bone 2004, 35:664-672.
11. Liao X, Tang S, Thrasher JB, Griebling T, Li B: Small-interfering
RNA-induced androgen receptor silencing leads to apoptotic
cell death in prostate cancer.  Mol Cancer Ther 2005, 4:505-515.
12. González-García M, Pérez-Ballestero R, Ding L, Duan L, Boise LH,
Thompson CB, Núñez G: bcl-XL is the major bcl-x mRNA form
expressed during murine development and its product local-
izes to mitochondria.  Development 1994, 120:3033-3042.
13. Sun A, Tang J, Hong Y, Song J, Terranova PF, Thrasher JB, Svojanovsky
S, Wang HG, Li B: Androgen receptor-dependent regulation of
Bcl-xL expression: Implication in prostate cancer progres-
sion.  Prostate 2008, 68:453-461.
14. Castilla C, Congregado B, Chinchón D, Torrubia FJ, Japón MA, Sáez
C:  Bcl-xL is overexpressed in hormone-resistant prostate
cancer and promotes survival of LNCaP cells via interaction
with proapoptotic Bak.  Endocrinology 2006, 147:4960-4967.
15. Yamanaka K, Rocchi P, Miyake H, Fazli L, So A, Zangemeister-Wittke
U, Gleave ME: Induction of apoptosis and enhancement of
chemosensitivity in human prostate cancer LNCaP cells
using bispecific antisense oligonucleotide targeting Bcl-2 and
Bcl-xL genes.  BJU Int 2006, 97:1300-1308.
16. Nemeth EF, Steffey ME, Hammerland LG, Hung BC, Van Wagenen
BC, DelMar EG, Balandrin MF: Calcimimetics with potent and
selective activity on the parathyroid calcium receptor.  Proc
Natl Acad Sci USA 1998, 95:4040-4045.
17. Pinton P, Giorgi C, Siviero R, Zecchini E, Rizzuto R: Calcium and
apoptosis: ER-mitochondria Ca2+ transfer in the control of
apoptosis.  Oncogene 2008, 27:6407-6418.
18. Chakravarti B, Dwivedi SK, Mithal A, Chattopadhyay N: Calcium-
sensing receptor in cancer: good cop or bad cop?  Endocrine
2009, 35(3):271-84.
19. Lin KI, Chattopadhyay N, Bai M, Alvarez R, Dang CV, Baraban JM,
Brown EM, Ratan RR: Elevated extracellular calcium can pre-
vent apoptosis via the calcium-sensing receptor.  Biochem Bio-
phys Res Commun 1998, 249:325-331.
20. Liao J, Schneider A, Datta NS, McCauley LK: Extracellular calcium
as a candidate mediator of prostate cancer skeletal metasta-
sis.  Cancer Res 2006, 66:9065-9073.
21. Wu Z, Tandon R, Ziembicki J, Nagano J, Hujer KM, Miller RT, Huang
C: Role of ceramide in Ca2+-sensing receptor-induced apop-
tosis.  J Lipid Res 2005, 46:1396-1404.